Vaxcyte, Inc. (PCVX) Institutional Ownership

Ownership Summary

Vaxcyte, Inc. (NASDAQ:PCVX) has 332 institutional investors with active 13F positions as of March 2026.

• These investors held 128.3% of outstanding shares in March 2026, up from 113.1% in December 2025.
• They increased total shares held in Vaxcyte by 28.6% from the prior quarter, while the number of investors in PCVX increased 5.06% year over year.
• During the quarter, 198 of these 332 funds increased positions in PCVX, 79 reduced exposure, and 55 held steady.
• The aggregate institutional position in Vaxcyte amounted to 179.02Mn shares as of March 2026, up by 39.81Mn shares quarter on quarter, and up 26.35Mn shares year over year.
• Janus Henderson Group Plc is the top holder of Vaxcyte as of March 31, 2026, with 33.15Mn shares representing 23.76% of outstanding stock.
• The largest buyers of Vaxcyte for the quarter ending March 2026 were Janus Henderson Group Plc (19.76Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.28Mn), VANGUARD CAPITAL MANAGEMENT LLC (6.27Mn), FMR LLC (2.66Mn), FARALLON CAPITAL MANAGEMENT, L.L.C. (1.26Mn).
• The biggest sellers of Vaxcyte for the quarter ending March 2026 included T. Rowe Price Investment Management, Inc. (5.85Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.38Mn), Goldman Sachs Group Inc (881.2K), D. E. Shaw & Co., Inc. (765.74K), State Street Corp (539.49K).
• Per Business Quant data, the top 10 holders of Vaxcyte for the quarter ending March 2026 are Janus Henderson Group Plc (33.15Mn), FMR LLC (16.49Mn), T. Rowe Price Investment Management, Inc. (12.13Mn), RA CAPITAL MANAGEMENT, L.P. (11.47Mn), BlackRock, Inc. (10.97Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.28Mn), VANGUARD CAPITAL MANAGEMENT LLC (6.27Mn), WELLINGTON MANAGEMENT GROUP LLP (5.61Mn), Paradigm Biocapital Advisors LP (4.79Mn), State Street Corp (4.44Mn).